eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac
Portal dla gastroenterologów!
SCImago Journal & Country Rank
vol. 13
Poleć ten artykuł:
streszczenie artykułu:
Artykuł oryginalny

Comparison between different first-line therapy protocols in eradicating Helicobacter pylori in a region with high clarithromycin resistance

Baris Yilmaz, Huseyin Koseoglu, Yusuf Coskun, Murat Deveci, Murat Kekilli

Data publikacji online: 2018/01/22
Pełna treść artykułu
Pobierz cytowanie
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero

Helicobacter pylori infection is encountered in more than 50% of the world population. A high rate of clarithromycin resistance is observed among Helicobacter pylori strains in some regions because clarithromycin is a drug commonly used for the treatment of other infections.

To identify an efficient eradication protocol for patients infected with H. pylori and to suggest an alternative first-line therapy particularly in countries with high clarithromycin resistance.

Material and methods
Patients (18–75 years old) having dyspeptic complaints in a 1-year period and diagnosed with H. pylori infection by gastric biopsy were included and randomised to three groups, each receiving different sequential eradication therapy (LAM-B: lansoprazole, amoxicillin, metronidazole, bismuth: LAM-T: lansoprazole, amoxicillin, metronidazole, tetracycline; LAM-BT: lansoprazole, amoxicillin, metronidazole, bismuth, tetracycline). Eradication was evaluated via urea breath test.

This study included 166 patients (mean age: 40 ±12 years; female, 68.7%) with H. pylori infection. Among them, 50 (30.1%) were in the LAM-B group, 59 (35.5%) were in the LAM-T group, and 57 (34.3%) were in the LAM-BT group. The non-steroidal anti-inflammatory drug use was the lowest in the LAM-BT group. Eradication rates were over 80% and similar in each group, with the highest rate in the LAM-BT group (93%). Adverse event rate was the highest in the LAM-T group. Helicobacter pylori eradication was achieved in 143 (86.1%) patients.

The combination regimens without clarithromycin achieved an eradication rate over 80% in all groups. Knowing and monitoring the regional antibiotic resistance rates is important for successful treatment of H. pylori infections.

Mitchell H, Katelaris P. Epidemiology, clinical impacts and current clinical management of Helicobacter pylori infection. Med J Aust 2016; 204: 376-80.
Plummer M, Franceschi S, Vignat J, et al. Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer 2015; 136: 487-90.
O’Connor A, Gisbert JP, McNamara D, et al. Treatment of Helicobacter pylori infection 2010. Helicobacter 2010; 15 Suppl 1: 46-52.
Martins GM, Sanches BS, Moretzsohn LD, et al. Molecular detection of clarithromycin and fluoroquinolones resistance in Helicobacter pylori infection, directly applied to gastric biopsies, in an urban Brazilian population. Arq Gastroenterol 2016; 53: 113-7.
Ji Z, Han F, Meng F, et al. The association of age and antibiotic resistance of Helicobacter pylori: a study in Jiaxing City, Zhejiang Province, China. Medicine (Baltimore) 2016; 95: e2831.
Hakemi Vala M, Eyvazi S, Goudarzi H, et al. Evaluation of clarithromycin resistance among Iranian Helicobacter pylori isolates by E-Test and real-time polymerase chain reaction methods. Jundishapur J Microbiol 2016; 9: e29839.
Alsohaibani F, Al Ashgar H, Al Kahtani K, et al. Prospective trial in Saudi Arabia comparing the 14-day standard triple therapy with the 10-day sequential therapy for treatment of Helicobacter pylori infection. Saudi J Gastroenterol 2015; 21: 220-5.
Tongtawee T, Dechsukhum C, Matrakool L, et al. High prevalence of Helicobacter pylori resistance to clarithromycin: a hospital-based cross-sectional study in Nakhon Ratchasima Province, Northeast of Thailand. Asian Pac J Cancer Prev 2015; 16: 8281-5.
Ozaydin N, Turkyilmaz SA, Cali S. Prevalence and risk factors of Helicobacter pylori in Turkey: a nationally-representative, cross-sectional, screening with the ¹³C-urea breath test. BMC Public Health 2013; 13: 1215.
Caliskan R, Tokman HB, Erzin Y, et al. Antimicrobial resistance of Helicobacter pylori strains to five antibiotics, including levofloxacin, in Northwestern Turkey. Rev Soc Bras Med Trop 2015; 48: 278-84.
Kaya AD, Oztürk CE, Akcan Y, et al. Prevalence of Helicobacter pylori in symptomatic patients and detection of clarithromycin resistance using melting curve analysis. Curr Ther Res Clin Exp 2007; 68: 151-60.
Onder G, Aydin A, Akarca U, et al. High Helicobacter pylori resistance rate to clarithromycin in Turkey. J Clin Gastroenterol 2007; 41: 747-50.
Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161-81.
Zhang M. High antibiotic resistance rate: a difficult issue for Helicobacter pylori eradication treatment. World J Gastroenterol 2015; 21: 13432-7.
Tong YF, Lv J, Ying LY, et al. Seven-day triple therapy is a better choice for Helicobacter pylori eradication in regions with low antibiotic resistance. World J Gastroenterol 2015; 21: 13073-9.
Franceschi F, Ojetti V, Gabrielli M, et al. High dose amoxicillin-based first line regimen is equivalent to sequential therapy in the eradication of H. pylorii infection. Eur Rev Med Pharmacol Sci 2016; 20: 297-300.
Chen YI, Fallone CA. A 14-day course of triple therapy is superior to a 10-day course for the eradication of Helicobacter pylori: a Canadian study conducted in a ‘real world’ setting. Can J Gastroenterol Hepatol 2015; 29: e7-10.
Haider RB, Brennan DE, Omorogbe J, et al. A randomized-controlled study to compare the efficacy of sequential therapy with standard triple therapy for Helicobacter pylori eradication in an Irish population. Eur J Gastroenterol Hepatol 2015; 27: 1265-9.
Gokcan H, Oztas E, Onal IK. Different bismuth-based therapies for eradicating Helicobacter pylori: randomized clinical trial of efficacy and safety. Clin Res Hepatol Gastroenterol 2016; 40: 124-31.
Songür Y, Senol A, Balkarli A, et al. Triple or quadruple tetracycline-based therapies versus standard triple treatment for Helicobacter pylori treatment. Am J Med Sci 2009; 338: 50-3.
Zhang W, Chen Q, Liang X, et al. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut 2015; 64: 1715-20.
Liou JM, Chen CC, Lee YC, et al.; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Systematic review with meta-analysis: 10- or 14-day sequential therapy vs. 14-day triple therapy in the first line treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2016; 43: 470-81.
Liou JM, Fang YJ, Chen CC, et al.; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2016; 388: 2355-65.
Uygun A, Kadayifci A, Safali M, et al. The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori. J Dig Dis 2007; 8: 211-5.
Alboraie M, Saad M, Al-Ali J, et al. Quadruple therapy versus standard triple therapy for eradication of Helicobacter pylori in Kuwait. Arab J Gastroenterol 2015; 16: 131-5.
Kim SE, Park MI, Park SJ, et al. Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy. Korean J Intern Med 2015; 30: 801-7.
Apostolopoulos P, Koumoutsos I, Ekmektzoglou K, et al. Concomitant versus sequential therapy for the treatment of Helicobacter pylori infection: a Greek randomized prospective study. Scand J Gastroenterol 2016; 51: 145-51.
Koivisto TT, Rautelin HI, Voutilainen ME, et al. First-line eradication therapy for Helicobacter pylori in primary health care based on antibiotic resistance: results of three eradication regimens. Aliment Pharmacol Ther 2005; 21: 773-82.
Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-81.
Chey WD, Wong BC. Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808-25.
Onal IK, Gokcan H, Benzer E, et al. What is the impact of Helicobacter pylori density on the success of eradication therapy: a clinico-histopathological study. Clin Res Hepatol Gastroenterol 2013; 37: 642-6.
Shah DK, Jain SS, Mohite A, et al. Effect of H. pylorii density by histopathology on its complications and eradication therapy. Trop Gastroenterol 2015; 36: 101-6.
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe